Abstract:Importance: Dysbiosis has been robustly demonstrated in Parkinson disease (PD), and fecal microbiota transplantation (FMT) has shown promising effects in preclinical PD models. Objective: To assess the safety and symptomatic efficacy of colonic single-dose anaerobically prepared FMT. Design, setting, and participants: This was a double-blind, placebo-controlled, randomized clinical trial conducted between November 2020 and June 2023 with a follow-up period of 12 months at 4 hospitals in Finland. Patients with PD aged 35 to 75 years in Hoehn & Yahr stage 1-3 with a mild to moderate symptom burden and dysbiosis of fecal microbiota were included. Of 229 patients screened, 48 were randomized and 47 received the intervention. One patient discontinued due to worsening of PD symptoms. Two further patients were excluded before analysis and 45 were included in the intention-to-treat analysis. Intervention: Participants were randomized in a 2:1 ratio to receive FMT or placebo via colonoscopy. Main outcomes and measures: The primary end point was the change of Movement Disorder Society Unified Parkinson's Disease Rating Scale parts I-III (part III off medication) at 6 months. Safety was assessed by recording adverse events (AEs). Results: The median (IQR) age was 65 (52.5-70.0) years in the placebo group and 66 (59.25-69.75) years in the FMT group; 9 (60.0%) and 16 (53.3%) patients were male in the placebo group and the FMT group, respectively. The primary outcome did not differ between the groups (0.97 points, 95% CI, -5.10 to 7.03, P = .75). Gastrointestinal AEs were more frequent in the FMT group (16 [53%] vs 1 [7%]; P = .003). Secondary outcomes and post hoc analyses showed stronger increase of dopaminergic medication and improvement of certain motor and nonmotor outcomes in the placebo group. Microbiota changes were more pronounced after FMT but differed by donor. Nevertheless, dysbiosis status was reversed more frequently in the placebo group. Conclusions and relevance: FMT was safe but did not offer clinically meaningful improvements. Further studies-for example, through modified FMT approaches or bowel cleansing-are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in PD. Trial registration: ClinicalTrials.gov Identifier: NCT04854291.

Fecal Microbiota Transplantation To Treat Parkinson'S Disease With Constipation A Case Report

Fecal Microbiota Transplantation for Parkinson's Patients with Constipation: A Pilot Clinical Trial

Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation

Fecal microbiota transplant as a potential treatment for Parkinson's disease – A case series

Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study

The Potential Role of Fecal Microbiota Transplantation in Parkinson’s Disease: A Systematic Literature Review

Probiotics for constipation and gut microbiota in Parkinson's disease

Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial

Fecal Microbiota Transplantation Modulates the Gut Flora Favoring Patients With Functional Constipation

Relationship among Parkinson’s disease, constipation, microbes, and microbiological therapy

Gut Microbiota and Parkinson's Disease: Implications for Faecal Microbiota Transplantation Therapy

Gut Microbiota and Parkinson’s Disease: Implications for Faecal Microbiota Transplantation Therapy

Potential role of fecal microbiota in patients with constipation

Outcomes and Prognostic Factors of Fecal Microbiota Transplantation in Patients with Slow Transit Constipation: Results from a Prospective Study with Long-Term Follow-Up

Treatment of Slow Transit Constipation With Fecal Microbiota Transplantation: A Pilot Study.

Gut microbiota and Parkinson's disease: potential links and the role of fecal microbiota transplantation

Efficacy and safety of fecal microbiota transplantation for the treatment of chronic functional constipation in the elderly

Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial

Fecal microbiota transplantation for Parkinson's disease using levodopa - carbidopa intestinal gel percutaneous endoscopic gastro-jejeunal tube

Fecal Microbiota Transplantation in Patients with Slow-Transit Constipation: A Randomized, Clinical Trial.

The Efficacy and Safety of Fecal Microbiota Transplantation Combined With Biofeedback for Mixed Constipation: A Retrospective Cohort Study